Trial Profile
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Citarinostat (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Acetylon Pharmaceuticals; Celgene Corporation
- 10 Oct 2023 Planned End Date changed from 2 Jul 2023 to 31 Jan 2024.
- 10 Oct 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Jan 2024.
- 11 Oct 2022 Planned End Date changed from 1 Jul 2023 to 2 Jul 2023.